Changes in Hong Kong stocks | Fu Hong Hanlin (02696) rose nearly 6%, and the company's core pipeline value continues to verify that H Pharmaceuticals will release US patient data for the first time

The Zhitong Finance App learned that Fu Hong Hanlin (02696) rose nearly 6%. As of press release, it had risen 5.83% to HK$58.95, with a turnover of HK$41.622,100.

According to the news, the 2026 European Society of Medical Oncology Annual Meeting will be held in Madrid, Spain from October 23 to 27. During this conference, Fu Hong Han Lin will present 12 research data, covering core tumor pipeline products such as the anti-PD-1 monoclonal antibody H drug Hansform®, PD-L1 ADC HLX43, and the innovative small molecule CDK4/6 inhibitor Futunin®, focusing on the latest advances and concept verification results in high-incidence cancers such as lung cancer, gastrointestinal tumors, and breast cancer. Among them, the HLX10-005-SCLC301E (ASTRIDE study) data from the bridging test HLX10-005-SCLC301E (ASTRIDE study) of the H drug independently developed by Fuhong Hanlin in the US will be read for the first time in the form of an oral report on Proffered Paper.

China Post Securities pointed out that the company's biosimilar business is driven by domestic and overseas two-wheel drives, and PD-1 has joined hands with many overseas giants to go global to provide steady cash flow for innovative research and development. The company's innovative pipelines HLX43 and HLX22 have shown potential best competitiveness, ushered in overseas opportunities, and are expected to open up the global market. The company has laid out a number of early pipelines with global competitiveness such as HLX3901 (quadruple antibody) and HLX3902 (triple antibody) in cutting-edge technology fields such as TCE and dual-antibody ADC, injecting strong impetus into long-term development.